WEKO3
アイテム
{"_buckets": {"deposit": "0eb01293-349e-4f14-ab4d-5cb414d750ab"}, "_deposit": {"created_by": 2, "id": "2948", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "2948"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00002948", "sets": ["214"]}, "author_link": ["13211", "13219", "13217", "13214", "13218", "13212", "13210", "13215", "13216", "13213"], "item_3_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2018-03", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "4", "bibliographicPageEnd": "157", "bibliographicPageStart": "151", "bibliographicVolumeNumber": "61", "bibliographic_titles": [{"bibliographic_title": "Acta medica Nagasakiensia"}]}]}, "item_3_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Objectives: Cases of schizophrenia are commonly complicated with obesity and diabetes mellitus partially caused by excessive eating associated with the use of second-generation antipsychotics (SGAs). We aimed to study the efficacy of glucagon-like peptide-1 in patients with schizophrenia under treatment with SGAs. Methods: Diabetic patients with schizophrenia were included if their HbA1c levels increased more than 1% and/or their weight increased more than 3 kg after treatment with SGAs. Patients who developed diabetes after treatment with SGAs were also included. The participants were treated with GLP-1 receptor agonists for one year, and their changes in weight and HbA1c and any adverse events were evaluated. Results: Seven patients were treated with GLP-1 receptor agonists; their mean age was 46.1 yrs old (range; 26 to 59), mean body weight was 85.3 kg (65.5 to 96.8), and mean BMI was 33.8 (27 to 38.7). Five of them showed improvement in their HbA1c levels of 1.2% (0.1 to 3.4, p=0.089) with a weight loss of 3.7 kg (-9.6 to +3.5, p=0.14) on average. The adverse effects observed were all gastrointestinal, but were not severe enough to cause termination of the GLP-1 receptor agonist treatment. The GLP-1 receptor agonist was not effective in one patient, and another patient terminated the treatment in a few months. Conclusions: Although the number of patients studied was small, GLP-1 receptor agonists seem to be effective for treating diabetes and bringing about weight loss in patients with schizophrenia under treatment with SGAs.", "subitem_description_type": "Abstract"}]}, "item_3_description_64": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Acta medica Nagasakiensia, 61(4), pp.151-157; 2018", "subitem_description_type": "Other"}]}, "item_3_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Nagasaki University School of Medicine"}]}, "item_3_source_id_10": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA00508430", "subitem_source_identifier_type": "NCID"}]}, "item_3_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "00016055", "subitem_source_identifier_type": "ISSN"}]}, "item_3_text_62": {"attribute_name": "sortkey", "attribute_value_mlt": [{"subitem_text_value": "03"}]}, "item_3_text_63": {"attribute_name": "出版者別言語", "attribute_value_mlt": [{"subitem_text_value": "長崎大学医学部"}]}, "item_3_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Ando, Takao"}], "nameIdentifiers": [{"nameIdentifier": "13210", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hatada, Keiko"}], "nameIdentifiers": [{"nameIdentifier": "13211", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sata, Misako"}], "nameIdentifiers": [{"nameIdentifier": "13212", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tachiki, Hitoshi"}], "nameIdentifiers": [{"nameIdentifier": "13213", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fukazawa, Tetsuro"}], "nameIdentifiers": [{"nameIdentifier": "13214", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kusumoto, Shiro"}], "nameIdentifiers": [{"nameIdentifier": "13215", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Horie, Ichiro"}], "nameIdentifiers": [{"nameIdentifier": "13216", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Abiru, Norio"}], "nameIdentifiers": [{"nameIdentifier": "13217", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Matsumoto, Shunji"}], "nameIdentifiers": [{"nameIdentifier": "13218", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kawakami, Atsushi"}], "nameIdentifiers": [{"nameIdentifier": "13219", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-21"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "ActMed61_151.pdf", "filesize": [{"value": "528.0 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 528000.0, "url": {"label": "ActMed61_151.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/2948/files/ActMed61_151.pdf"}, "version_id": "fe4c2178-222e-4f35-ac4a-b466ddb3d84e"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "GLP-1 receptor agonist", "subitem_subject_scheme": "Other"}, {"subitem_subject": "schizophrenia", "subitem_subject_scheme": "Other"}, {"subitem_subject": "second-generation antipsychotics", "subitem_subject_scheme": "Other"}, {"subitem_subject": "weight gain", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Glucagon-like peptide-1 receptor agonists as an effective therapeutic agent for diabetes mellitus and obesity in patients with schizophrenia under treatment with second-generation antipsychotics", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Glucagon-like peptide-1 receptor agonists as an effective therapeutic agent for diabetes mellitus and obesity in patients with schizophrenia under treatment with second-generation antipsychotics"}]}, "item_type_id": "3", "owner": "2", "path": ["214"], "permalink_uri": "http://hdl.handle.net/10069/38191", "pubdate": {"attribute_name": "公開日", "attribute_value": "2018-05-10"}, "publish_date": "2018-05-10", "publish_status": "0", "recid": "2948", "relation": {}, "relation_version_is_last": true, "title": ["Glucagon-like peptide-1 receptor agonists as an effective therapeutic agent for diabetes mellitus and obesity in patients with schizophrenia under treatment with second-generation antipsychotics"], "weko_shared_id": 2}
Glucagon-like peptide-1 receptor agonists as an effective therapeutic agent for diabetes mellitus and obesity in patients with schizophrenia under treatment with second-generation antipsychotics
http://hdl.handle.net/10069/38191
http://hdl.handle.net/10069/3819184842206-66a9-4810-957d-5c0c22310f1a
名前 / ファイル | ライセンス | アクション |
---|---|---|
ActMed61_151.pdf (528.0 kB)
|
|
Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2018-05-10 | |||||
タイトル | ||||||
タイトル | Glucagon-like peptide-1 receptor agonists as an effective therapeutic agent for diabetes mellitus and obesity in patients with schizophrenia under treatment with second-generation antipsychotics | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | GLP-1 receptor agonist | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | schizophrenia | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | second-generation antipsychotics | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | weight gain | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | departmental bulletin paper | |||||
著者 |
Ando, Takao
× Ando, Takao× Hatada, Keiko× Sata, Misako× Tachiki, Hitoshi× Fukazawa, Tetsuro× Kusumoto, Shiro× Horie, Ichiro× Abiru, Norio× Matsumoto, Shunji× Kawakami, Atsushi |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Objectives: Cases of schizophrenia are commonly complicated with obesity and diabetes mellitus partially caused by excessive eating associated with the use of second-generation antipsychotics (SGAs). We aimed to study the efficacy of glucagon-like peptide-1 in patients with schizophrenia under treatment with SGAs. Methods: Diabetic patients with schizophrenia were included if their HbA1c levels increased more than 1% and/or their weight increased more than 3 kg after treatment with SGAs. Patients who developed diabetes after treatment with SGAs were also included. The participants were treated with GLP-1 receptor agonists for one year, and their changes in weight and HbA1c and any adverse events were evaluated. Results: Seven patients were treated with GLP-1 receptor agonists; their mean age was 46.1 yrs old (range; 26 to 59), mean body weight was 85.3 kg (65.5 to 96.8), and mean BMI was 33.8 (27 to 38.7). Five of them showed improvement in their HbA1c levels of 1.2% (0.1 to 3.4, p=0.089) with a weight loss of 3.7 kg (-9.6 to +3.5, p=0.14) on average. The adverse effects observed were all gastrointestinal, but were not severe enough to cause termination of the GLP-1 receptor agonist treatment. The GLP-1 receptor agonist was not effective in one patient, and another patient terminated the treatment in a few months. Conclusions: Although the number of patients studied was small, GLP-1 receptor agonists seem to be effective for treating diabetes and bringing about weight loss in patients with schizophrenia under treatment with SGAs. | |||||
書誌情報 |
Acta medica Nagasakiensia 巻 61, 号 4, p. 151-157, 発行日 2018-03 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 00016055 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA00508430 | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
出版者 | ||||||
出版者 | Nagasaki University School of Medicine | |||||
出版者別言語 | ||||||
長崎大学医学部 | ||||||
sortkey | ||||||
03 | ||||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Acta medica Nagasakiensia, 61(4), pp.151-157; 2018 |